Long-Term Cancer Survival: New Insights From Health Professional Cohorts
Menée à partir de données 1976-2013 des cohortes "the Nurses’ Health Studies" et "the Health Professionals Follow-Up Study" portant sur 28 448 femmes et 13 556 hommes atteints d'un cancer (prostate, poumon, côlon/rectum, vessie, mélanome, sein, col utérin, thyroïde), cette étude analyse la mortalité cumulée globale et spécifique 30 ans après le diagnostic chez les hommes et 35 ans après chez les femmes
As clinicians are well-aware, the first question posed by someone receiving a new cancer diagnosis is: “How long will I live?” The response hinges on the stage of the disease, the aggressiveness of the malignancy, treatment options, and the underlying health of the patient. Longevity then depends on the success of treatment, the holistic impact of the diagnosis on the patient’s health and well-being, and broadly, on the social determinants of health as they intersect with the patient. Additionally, some factors increasing risk for incident cancers, e.g., cigarette smoking, are causally linked to diseases shortening lifespan and to increased risk for a second malignancy. Treatments for the primary cancer, both radiation and chemotherapy, may also increase risk for a second cancer.
JNCI Cancer Spectrum 2022